Andros Pharmaceuticals Co (ROCO:6917) Total Payout Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
47 GF Score
Price NT$38.00
GF Value NT$268.36
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Andros Pharmaceuticals Co's current Total Payout Ratio is .

Andros Pharmaceuticals Co Total Payout Ratio Related Terms

Andros Pharmaceuticals Co Total Payout Ratio Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co Total Payout Ratio Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Ratio
- - - - -

Andros Pharmaceuticals Co Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only - - - - -

ROCO:6917 vs VRTX, REGN, MRNA: Total Payout Ratio Comparison

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co Total Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Total Payout Ratio falls into.


ROCO:6917
47GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
Total Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Andros Pharmaceuticals Co's Total Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 175 + -0) / -53.776
=3.25

Andros Pharmaceuticals Co's Total Payout Ratio for the quarter that ended in Jun. 2026 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (-0 + 0 + -0) / -25.822
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$38.00 is trading 85.8% below its estimated GF Value™ of NT$268.36. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • Total Payout Ratio:
  • GF Value™: NT$268.36 vs. price of NT$38.00 (85.8% below fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
47GF Score

Get the complete analysis for ROCO:6917

Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.00
Price
NT$268.36
GF Value